Market revenue in 2023 | USD 12,029.9 million |
Market revenue in 2030 | USD 17,126.7 million |
Growth rate | 5.2% (CAGR from 2023 to 2030) |
Largest segment | Clinical |
Fastest growing segment | Pre-Clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Drug Discovery, Pre-Clinical, Clinical |
Key market players worldwide | Icon PLC, Charles River Laboratories International Inc, IQVIA Holdings Inc, GVK Biosciences, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, PAREXEL, Dassault Systemes SE, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, SGS AG, Worldwide Clinical Trials, Wuxi AppTec Co Ltd, Caidya |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to healthcare contract research organization market will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 75.83% in 2023. Horizon Databook has segmented the U.S. healthcare contract research organization market based on drug discovery, pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
The pharmaceutical industry in the U.S. is strong, and research firms devote almost one-fifth of their earnings to R&D. The cost of developing a new drug is high; after 10 years of work, it can reach USD 2.6 billion.
About half of global medical R&D is financed by the U.S. market, according to a 2018 Council of Economic Advisers report. Biologics accounted for USD 211 billion, or 43%, of all medical spending in the U.S. in 2019.
Even though biosimilars for only 11 molecules have emerged, the development & approval of biosimilars has accelerated, with 33 approvals across 13 molecules. Biosimilars have the potential to generate USD 80 billion in revenue over the next 5 years, with USD 16 billion–36 billion generated in 2024.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. healthcare contract research organization market , including forecasts for subscribers. This country databook contains high-level insights into U.S. healthcare contract research organization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account